|Articles|September 1, 2001

Depression and Generalized Anxiety Disorder: Managed Care Considerations
Volume 7
Issue 11 Suppl

The Clinical, Psychosocial, and Pharmacoeconomic Ramifications of Remission

Author(s)Michael E. Thase, MD

Download PDF: The Clinical, Psychosocial, and Pharmacoeconomic Ramifications of Remission

Articles in this issue

almost 25 years ago

Article

Participating Faculty

almost 25 years ago

Article

Introduction

almost 25 years ago

Article

Current Perspectives on the Diagnosis and Treatment of Major Depressive Disorder

almost 25 years ago

Article

Recent Perspectives on the Diagnosis and Treatment of Generalized Anxiety Disorder

almost 25 years ago

Article

The Pharmacoeconomics of Venlafaxine in Depression

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

The Clinical, Psychosocial, and Pharmacoeconomic Ramifications of Remission

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

Lipoprotein(a): An FAQ on Awareness, Risk, and Screening Gaps

Gene Therapy for Wet AMD Near an Inflection Point: Arshad Khanani, MD

Senate Unveils Sweeping Bill to Reform 340B Drug Program

Severe Eczema More Than Doubles Shingles Risk

Occupational Triggers Fuel Half of CHE Cases, Spanish Study Finds

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

The Clinical, Psychosocial, and Pharmacoeconomic Ramifications of Remission

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

Lipoprotein(a): An FAQ on Awareness, Risk, and Screening Gaps

Gene Therapy for Wet AMD Near an Inflection Point: Arshad Khanani, MD

Senate Unveils Sweeping Bill to Reform 340B Drug Program

Severe Eczema More Than Doubles Shingles Risk

Occupational Triggers Fuel Half of CHE Cases, Spanish Study Finds